Cat. No.: HY-151527

PI3K/Akt/CREB activator 1

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).

For research use only. We do not sell to patients.

Purity: 98.64%
CAS No.: 2708177-73-3
Formula: C₁₉H₁₅F₄NO₃
Molecular Weight:381.32

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

PI3K/Akt/CREB activator 1 Chemical Structure

CAS No.: 2708177-73-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Akt Isoforms :

All PI3K Isoforms :

All Epigenetic Reader Domain Isoforms :

In Vitro

PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells^[1].
PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Neuro-2a cells
Concentration:

10 and 20 μM
Incubation Time:

48 hours
Result:

Increased the expressions of BDNF and the phosphorylated form of AKT (pAKT) and CREB (pCREB).

In Vivo

PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO)^[1].
PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model^[1]
Dosage:

5 and 10 mg/kg
Administration:

Oral gavage; daily, for 6 weeks
Result:

Promoted the recovery of CBF after BCCAO.

Animal Model:

Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model^[1]
Dosage:

5 and 10 mg/kg
Administration:

Oral gavage; daily, for 5 days
Result:

Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group.
Improved cognitive deficits in CCH rat model.

Chemical Information

CAS No. 2708177-73-3
Appearance Solid
Molecular Weight 381.32
Formula C₁₉H₁₅F₄NO₃
Color White to off-white
SMILES

O=C(N[C@H](C(O)=O)CC1=CC=C(C=C1)F)/C=C/C2=CC=C(C=C2)C(F)(F)F
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All Cell Proliferation/Viability AssayApoptosis AnalysisFlow CytometryWBRT-PCR

Sort by:

Journal Impact Factor

Cell Rep

Post-stroke hippocampal neurogenesis is impaired by microvascular dysfunction and PI3K signaling in cerebral amyloid angiopathy. [Abstract]

2024 Oct 10;43(10):114848. PMID: 39392753
Eur J Pharmacol

Bufotalin targets COL1A1 to suppress non-small cell lung cancer growth and remodel the tumor microenvironment via dual inhibition of PI3K/AKT/mTOR and MAPK pathways. [Abstract]

2026 Feb 15:1015:178601. PMID: 41581717
Discov Oncol

Celastrol inhibits mouse B16-F10 melanoma cell survival by regulating the PI3K/AKT/mTOR signaling pathway and repressing HIF-1α expression. [Abstract]

2024 May 21;15(1):178. PMID: 38771435

PI3K/Akt/CREB activator 1 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2024 May 21;15(1):178. [Abstract]

B16-F10 cells were treated with different concentrations of PI3K activator (0, 10, 20, 30, and 50 μM) at 12, 24, 36, and 48 h, and the cell viability was detected using a CCK8 assay.

PI3K/Akt/CREB activator 1 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2024 May 21;15(1):178. [Abstract]

The apoptosis rate of B16-F10 cells was detected by flow cytometry treated with PI3K activator (50 μM).

PI3K/Akt/CREB activator 1 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2024 May 21;15(1):178. [Abstract]

The cell cycle was evaluated by flow cytometry treated with PI3K activator (50 μM).

PI3K/Akt/CREB activator 1 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2024 May 21;15(1):178. [Abstract]

The levels of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR were detected using western blotting treated with PI3K activator (50 μM).

PI3K/Akt/CREB activator 1 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2024 May 21;15(1):178. [Abstract]

The expression of HIF-α mRNA in B16-F10 cells was detected by qPCR after co-culture with celastrol and PI3K activator (50 μM).
University of Miami

2025.

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (655.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6225 mL

13.1123 mL

26.2247 mL

5 mM

0.5245 mL

2.6225 mL

5.2449 mL

10 mM

0.2622 mL

1.3112 mL

2.6225 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Feng JH, et, al. Protective Effects of 4-Trifluoromethyl-(E)-cinnamoyl]-L-4-F-phenylalanine Acid against Chronic Cerebral Hypoperfusion Injury through Promoting Brain-Derived Neurotrophic Factor-Mediated Neurogenesis. ACS Chem Neurosci. 2022 Oct 16. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6225 mL	13.1123 mL	26.2247 mL	65.5617 mL
	5 mM	0.5245 mL	2.6225 mL	5.2449 mL	13.1123 mL
	10 mM	0.2622 mL	1.3112 mL	2.6225 mL	6.5562 mL
	15 mM	0.1748 mL	0.8742 mL	1.7483 mL	4.3708 mL
	20 mM	0.1311 mL	0.6556 mL	1.3112 mL	3.2781 mL
	25 mM	0.1049 mL	0.5245 mL	1.0490 mL	2.6225 mL
	30 mM	0.0874 mL	0.4371 mL	0.8742 mL	2.1854 mL
	40 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6390 mL
	50 mM	0.0524 mL	0.2622 mL	0.5245 mL	1.3112 mL
	60 mM	0.0437 mL	0.2185 mL	0.4371 mL	1.0927 mL
	80 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6556 mL

Keywords

PI3K/Akt/CREB activator 1

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PI3K/Akt/CREB activator 1

Bioactive Compound Library Max

Bioactive Compound Library

Epigenetics Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Histone Modification Research Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Cysteine Targeted Covalent Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) PI3K/Akt/CREB activator 1

All Akt Isoforms

All PI3K Isoforms

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

PI3K/Akt/CREB activator 1 Related Classifications

HY-151527 Related Classifications